Tonix Pharmaceuticals Holdings Corp. Prices $70M Common Stock Offering Priced At-The-Market Under Nasdaq Rules
February 08, 2021 10:30 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Feb. 08, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has...
Tonix Pharmaceuticals to Develop COVID-19 Skin Test (TNX-2100) to Measure SARS-CoV-2 Exposure and T Cell Immunity
February 08, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Pre-IND Meeting Written Response from FDA Provides Guidance on Product Development and Clinical Testing Protocol Intradermal Test is Designed to Measure SARS-CoV-2 Specific Delayed Type...
Tonix Pharmaceuticals Announces Publication of Patent Application for TNX-1500 (Monoclonal Antibody Anti-CD40-Ligand) in Development for Preventing and Treating Organ Transplant Rejection and Treating Autoimmune Conditions
January 14, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
GMP Production of TNX-1500 is Expected to be Available in the Third Quarter of 2021 CHATHAM, N.J., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the...
Tonix Pharmaceuticals Holdings Corp. Closes $40M Common Stock Offering Priced At-the-Market Under Nasdaq Rules
January 13, 2021 16:05 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Jan. 13, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced the...
Tonix Pharmaceuticals Holdings Corp. Prices $40M Common Stock Offering Priced at-the-Market Under Nasdaq Rules
January 11, 2021 12:59 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Jan. 11, 2021 (GLOBE NEWSWIRE) -- TONIX PHARMACEUTICALS HOLDINGS CORP. (NASDAQ: TNXP) (“Tonix” or the “Company”), a clinical-stage biopharmaceutical company, today announced it has...
Tonix Pharmaceuticals to Participate in Upcoming January Conferences
January 05, 2021 16:15 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that Seth...
Tonix Pharmaceuticals and Massachusetts General Hospital (MGH) Enter into Research Collaboration on Tonix’s Third Generation anti-CD40-Ligand Monoclonal Antibody, TNX-1500, for the Treatment and Prevention of Kidney Transplant Rejection
January 05, 2021 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Expands Ongoing Research Collaboration Between Tonix and MGH Studying TNX-1500 in Heart Transplantation TNX-1500 May Hold Potential in Treating Autoimmune Diseases Including Systemic Lupus...
Tonix Pharmaceuticals Plans Commercial Scale Vaccine Manufacturing Facility
December 23, 2020 09:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Hamilton, MT Facility Is Planned to Manufacture Vaccines at Commercial Scale, Including Vaccines Under Development for COVID-19 CHATHAM, N.J., Dec. 23, 2020 (GLOBE NEWSWIRE) -- Tonix...
Tonix Pharmaceuticals Acquires Exclusive License to University of Geneva Technology for Oxytocin-Based Treatments for Treating Insulin Resistance, Diabetes and Obesity, Expanding Proprietary Uses for TNX-1900 (Intranasal Potentiated Oxytocin)
December 22, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
CHATHAM, N.J., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement...
Tonix Pharmaceuticals Reports Topline Results from Phase 3 RECOVERY Study of TNX-102 SL in PTSD and Outlines Future Development Plans
December 21, 2020 07:00 ET
|
Tonix Pharmaceuticals Holding Corp.
Primary Endpoint For Full Cohort of Enrolled Participants Did Not Achieve Statistical Significance (P=0.343), Consistent with Previously Reported Interim Analysis Encouraging Activity of TNX-102 SL...